Open an account

Repligen

RGEN · NASDAQ

$178.88+$2.45 (+1.39%)TodayMarket closed ·
Prev close $176.43

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,000 full-time employees. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.

Employees
2,000
Headquarters
Waltham, Massachusetts
Listed
Apr 29, 1986
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
repligen.com

RGEN key statistics

Market cap
11.36B
Price-earnings ratio
241.68
Dividend yield
—
Average volume
1.31M
Volume
877.82K
Open price
$176.50
High today
$180.67
Low today
$174.37
52 Week high
$196.65
52 Week low
$100.99

Repligen (RGEN) at a glance

As of Oct 20, 2026, Repligen (RGEN) shares are priced at $178.88, giving the company a market cap of 11.36B and a price-to-earnings ratio of 241.68.

Today the stock has traded between $174.37 and $180.67. The current price is 2.6% above the day's low and 1.0% below its high.

Volume so far is 877.82K shares, below the average of 1.31M shares a day.

Over the past year Repligen has ranged from $100.99 to $196.65, and now sits 81% of the way up that range.

Repligen met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.54 per share against an estimate of $0.4576.

The average analyst price target is $194.88, 8.9% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 12 analyst ratings say Buy
  • Buy91.7%
  • Hold8.3%
  • Sell0.0%
Price target · 21 analystsAvg $194.88
Low
$146.45
Now
$178.88
High
$236.25

RGEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 14.1% on average.

  1. Q3 FY24: reported $0.43 per share against an estimate of $0.3416
  2. Q4 FY24: reported $0.44 per share against an estimate of $0.4182
  3. Q1 FY25: reported $0.39 per share against an estimate of $0.3522
  4. Q2 FY25: reported $0.37 per share against an estimate of $0.3971
  5. Q3 FY25: reported $0.46 per share against an estimate of $0.4268
  6. Q4 FY25: reported $0.49 per share against an estimate of $0.4485
  7. Q1 FY26: reported $0.48 per share against an estimate of $0.3938
  8. Q2 FY26: reported $0.54 per share against an estimate of $0.4576

RGEN news

  • Press releasePRNewswire

    Freshworks Set to Join S&P SmallCap 600

  • Press releaseBusiness Wire

    BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseBusiness Wire

    BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

  • Vandana Singh

    Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

  • Repligen Earnings Preview

  • Press releaseBusiness Wire

    908 Devices Appoints Christopher D. Brown to its Board of Directors

  • Vandana Singh

    908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Similar companies

Companies in the same industry as Repligen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.